110 related articles for article (PubMed ID: 12920198)
21. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
Rioux L; Frohna PA; Joyce JN; Schneider JS
Mov Disord; 1997 Mar; 12(2):148-58. PubMed ID: 9087972
[TBL] [Abstract][Full Text] [Related]
22. 5-Iodo-A-85380 binds to alpha-conotoxin MII-sensitive nicotinic acetylcholine receptors (nAChRs) as well as alpha4beta2* subtypes.
Kulak JM; Sum J; Musachio JL; McIntosh JM; Quik M
J Neurochem; 2002 Apr; 81(2):403-6. PubMed ID: 12064487
[TBL] [Abstract][Full Text] [Related]
23. Melatonin synergizes with low doses of L-DOPA to improve dendritic spine density in the mouse striatum in experimental Parkinsonism.
Naskar A; Manivasagam T; Chakraborty J; Singh R; Thomas B; Dhanasekaran M; Mohanakumar KP
J Pineal Res; 2013 Oct; 55(3):304-12. PubMed ID: 23952687
[TBL] [Abstract][Full Text] [Related]
24. Contribution of brain serotonin subtype 1B receptors in levodopa-induced motor complications.
Morin N; Morissette M; Grégoire L; Rajput A; Rajput AH; Di Paolo T
Neuropharmacology; 2015 Dec; 99():356-68. PubMed ID: 26254863
[TBL] [Abstract][Full Text] [Related]
25. Chronic oral nicotine normalizes dopaminergic function and synaptic plasticity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates.
Quik M; Chen L; Parameswaran N; Xie X; Langston JW; McCallum SE
J Neurosci; 2006 Apr; 26(17):4681-9. PubMed ID: 16641249
[TBL] [Abstract][Full Text] [Related]
26. Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
Morin N; Jourdain VA; Morissette M; Grégoire L; Di Paolo T
Neuropharmacology; 2014 Apr; 79():688-706. PubMed ID: 24456747
[TBL] [Abstract][Full Text] [Related]
27. Differential alterations in nicotinic receptor alpha6 and beta3 subunit messenger RNAs in monkey substantia nigra after nigrostriatal degeneration.
Quik M; Polonskaya Y; Gillespie A; K Lloyd G; Langston JW
Neuroscience; 2000; 100(1):63-72. PubMed ID: 10996459
[TBL] [Abstract][Full Text] [Related]
28. AQW051, a novel and selective nicotinic acetylcholine receptor α7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys.
Di Paolo T; Grégoire L; Feuerbach D; Elbast W; Weiss M; Gomez-Mancilla B
Parkinsonism Relat Disord; 2014 Nov; 20(11):1119-23. PubMed ID: 25172125
[TBL] [Abstract][Full Text] [Related]
29. Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys.
Morin N; Morissette M; Grégoire L; Gomez-Mancilla B; Gasparini F; Di Paolo T
Neuropharmacology; 2013 Oct; 73():216-31. PubMed ID: 23756168
[TBL] [Abstract][Full Text] [Related]
30. Pharmacology of alpha-conotoxin MII-sensitive subtypes of nicotinic acetylcholine receptors isolated by breeding of null mutant mice.
Salminen O; Drapeau JA; McIntosh JM; Collins AC; Marks MJ; Grady SR
Mol Pharmacol; 2007 Jun; 71(6):1563-71. PubMed ID: 17341654
[TBL] [Abstract][Full Text] [Related]
31. Expression of nigrostriatal alpha 6-containing nicotinic acetylcholine receptors is selectively reduced, but not eliminated, by beta 3 subunit gene deletion.
Gotti C; Moretti M; Clementi F; Riganti L; McIntosh JM; Collins AC; Marks MJ; Whiteaker P
Mol Pharmacol; 2005 Jun; 67(6):2007-15. PubMed ID: 15749993
[TBL] [Abstract][Full Text] [Related]
32. Evidence for a role for α6(∗) nAChRs in l-dopa-induced dyskinesias using Parkinsonian α6(∗) nAChR gain-of-function mice.
Bordia T; McGregor M; McIntosh JM; Drenan RM; Quik M
Neuroscience; 2015 Jun; 295():187-97. PubMed ID: 25813704
[TBL] [Abstract][Full Text] [Related]
33. Striatal Akt/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys.
Morissette M; Samadi P; Hadj Tahar A; Bélanger N; Di Paolo T
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Apr; 34(3):446-54. PubMed ID: 20026151
[TBL] [Abstract][Full Text] [Related]
34. Differential regulation of mesolimbic alpha 3/alpha 6 beta 2 and alpha 4 beta 2 nicotinic acetylcholine receptor sites and function after long-term oral nicotine to monkeys.
McCallum SE; Parameswaran N; Bordia T; Fan H; McIntosh JM; Quik M
J Pharmacol Exp Ther; 2006 Jul; 318(1):381-8. PubMed ID: 16622038
[TBL] [Abstract][Full Text] [Related]
35. Nicotinic receptor agonists reduce L-DOPA-induced dyskinesias in a monkey model of Parkinson's disease.
Zhang D; Mallela A; Sohn D; Carroll FI; Bencherif M; Letchworth S; Quik M
J Pharmacol Exp Ther; 2013 Oct; 347(1):225-34. PubMed ID: 23902940
[TBL] [Abstract][Full Text] [Related]
36. 125I-alpha-conotoxin MII identifies a novel nicotinic acetylcholine receptor population in mouse brain.
Whiteaker P; McIntosh JM; Luo S; Collins AC; Marks MJ
Mol Pharmacol; 2000 May; 57(5):913-25. PubMed ID: 10779374
[TBL] [Abstract][Full Text] [Related]
37. Levodopa induces long-lasting modification in the functional activity of the nigrostriatal pathway.
Riverol M; Ordóñez C; Collantes M; DiCaudo C; Peñuelas I; Arbizu J; Marcilla I; Luquin MR
Neurobiol Dis; 2014 Feb; 62():250-9. PubMed ID: 24076099
[TBL] [Abstract][Full Text] [Related]
38. Involvement of the alpha3 subunit in central nicotinic binding populations.
Whiteaker P; Peterson CG; Xu W; McIntosh JM; Paylor R; Beaudet AL; Collins AC; Marks MJ
J Neurosci; 2002 Apr; 22(7):2522-9. PubMed ID: 11923417
[TBL] [Abstract][Full Text] [Related]
39. Nanomolar L-dopa facilitates release of dopamine via presynaptic beta-adrenoceptors: comparative studies on the actions in striatal slices from control and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 black mice, an animal model for Parkinson's disease.
Goshima Y; Misu Y; Arai N; Misugi K
Jpn J Pharmacol; 1991 Jan; 55(1):93-100. PubMed ID: 1645816
[TBL] [Abstract][Full Text] [Related]
40. Time-course and dose-response study on the effects of chronic L-DOPA administration on striatal dopamine levels and dopamine transporter following MPTP toxicity.
Fornai F; Battaglia G; Gesi M; Giorgi FS; Orzi F; Nicoletti F; Ruggieri S
Brain Res; 2000 Dec; 887(1):110-7. PubMed ID: 11134595
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
